Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team of medical professors from Zhejiang, China, released the results of a clinical trial demonstrating the breakthrough effectiveness of fourth-generation anti-CD19 CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study, published in the renowned journal *Cell Discovery* (“Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma”), sheds light on this innovative approach.
**New Highlights of CAR-T Therapy**
Traditional anti-CD19 CAR-T cell therapy has already shown excellent efficacy in treating blood cancers like R/R LBCL, but tumor relapse remains a significant challenge. To address this, Chinese researchers have developed a new fourth-generation CAR-T cell therapy that co-expresses two cytokines, IL-7 and CCL19. These cytokines enhance the activity of immune cells, improving CAR-T cells’ anti-tumor effects and extending patient survival.
**Efficacy and Potential**
The Chinese medical team included 39 patients, aged 29 to 73, in this study. They received a single infusion of the fourth-generation anti-CD19 CAR-T cells co-expressing IL-7/CCL19. The results showed that within three months of treatment, the overall response rate (ORR) reached 79.5%, with a complete response rate (CR) of 56.4%. This therapy also demonstrated a notable long-lasting effect, with a median progression-free survival (PFS) of 13 months, and an estimated two-year overall survival rate (OS) of 53.8%.
The study found that the expansion of CAR-T cells in the blood and plasma levels of IL-7/CCL19 were closely associated with clinical outcomes. Higher CAR-T cell expansion and peak concentrations of IL-7/CCL19 were linked to better overall survival (OS), further confirming that this combination can enhance CAR-T cells’ anti-tumor potential.
**Why Is This Study So Important?**
The introduction of this new CAR-T therapy in China marks a significant leap forward in cancer treatment. It not only induces long-lasting remission but also significantly extends patient survival, with manageable safety, offering new hope to patients facing resistant blood cancers. China’s rapid advancements in CAR-T technology showcase its growing influence in the global biotechnology sector.
This groundbreaking research not only solidifies China’s important position in medical innovation but also lays the foundation for future development and application of more CAR-T therapies, potentially bringing revolutionary changes to cancer treatment worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
